Lecanemab‐associated amyloid‐β protofibril is a proximal biomarker of neurodegeneration unlike other plaque‐associated biomarkers
Kenjiro Ono, Moeko Shinohara, Kazuyoshi Shuta, Hidetomo Murakami, Yukiko Mori, Junji Komatsu, Chizuru Kobayashi, Steven Hersch, Kanta Horie · 2025
Read Lecanemab‐associated amyloid‐β protofibril is a proximal biomarker of neurodegeneration unlike other plaque‐associated biomarkers by Kenjiro Ono, Moeko Shinohara, Kazuyoshi Shuta, Hidetomo Murakami, Yukiko Mori, Junji Komatsu, Chizuru Kobayashi, Steven Hersch, Kanta Horie (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712824.txt.
Description
Alzheimer's drugs that hunt amyloid can also be turned into measuring tools. Kenjiro Ono and eight co-authors use the antibody lecanemab to fish a specific amyloid form, the soluble protofibril, out of spinal fluid in this 2025 study. Nearly one hundred and fifty people took part, from young healthy controls to patients with full dementia.
The caught protofibril levels ran high in mild impairment and dementia groups, and even stirred upward in symptom-free people whose scans already showed amyloid. That early rise, tracking closely with brain damage markers, sets it apart from plaque-based measures, which mostly report the load of finished deposits. The authors argue the protofibril is the form closest to the injury itself, making it a candidate marker for when treatment should start. A negative-scan patient group showed no such rise.
Catalog record
| CREATOR | Kenjiro Ono, Moeko Shinohara, Kazuyoshi Shuta, Hidetomo Murakami, Yukiko Mori, Junji Komatsu, Chizuru Kobayashi, Steven Hersch, Kanta Horie |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |